Copyright
©The Author(s) 2021.
World J Gastrointest Oncol. Nov 15, 2021; 13(11): 1696-1708
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1696
Published online Nov 15, 2021. doi: 10.4251/wjgo.v13.i11.1696
Ref. | Study design | Treatment | No. of patients | Outcomes | Complications/Adverse events |
Hsiao et al[13] | Single-center, single-arm, retrospective | IRE | 9 | Median overall survival: 26 mo; progression-free survival: 18 mo | None reported |
Martin et al[14] | Single-center, single-arm, retrospective | IRE | 26 | Median survival without biliary drainage: 305 d (range 92–458); disease-free: 11.5% | Complications: 3/26 (11.5%; severe 7.7%) |
Li et al[18] | Single-center, comparative, retrospective | PDT + stent vs stent-only | 62 (30 vs 32) | Median survival: PDT + stent 14.2 vs stent-only 9.8 mo, P = 0.003 | Adverse events: 24 (38.7%) vs 20 (29.0%), P = 0.239 |
Mizandari et al[22] | Single-center, single-arm, retrospective | Endobiliary RFA | 39 | Median survival: 89.5 d (range 14-260) | None reported |
Andrašina et al[27] | Single-center, prospective, multimodal oncological therapy | TACE or IA chemotherapy with or without SC vs IV SC | 40 (17 vs 23) | Median overall survival: 13.5 mo (range, 11.0-18.8 mo). Median overall survival IA: 25.2 mo (range, 15.2-31.3 mo) vs IV SC 11.5 mo (range, 8.5-12.6 mo) in (P < 0.05) | None reported |
- Citation: Inchingolo R, Acquafredda F, Ferraro V, Laera L, Surico G, Surgo A, Fiorentino A, Marini S, de'Angelis N, Memeo R, Spiliopoulos S. Non-surgical treatment of hilar cholangiocarcinoma. World J Gastrointest Oncol 2021; 13(11): 1696-1708
- URL: https://www.wjgnet.com/1948-5204/full/v13/i11/1696.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v13.i11.1696